Abstract
Purpose of Review: The treatment landscape of multiple myeloma (MM) has evolved resulting in MM becoming a chronic condition. The costs of MM therapies are substantial and compound as patients remain on long-term maintenance therapies and progress through multiple lines of high-cost therapies. MM predominantly impacts the elderly population insured by Medicare; here, we analyze how these costs impact patients and the Medicare trust fund. Recent Findings: With the recent passing of the Inflation Reduction Act (IRA), we postulate how costs may be impacted and debate future policy initiatives that may result in sustainability. Summary: The IRA will impact drug pricing and likely reduce the costs of some treatments used in MM; there is still a lot of room for policy reform to reduce financial toxicity to patients and prevent depletion of the Medicare trust fund.
Original language | English (US) |
---|---|
Pages (from-to) | 201-215 |
Number of pages | 15 |
Journal | Current Hematologic Malignancy Reports |
Volume | 18 |
Issue number | 5 |
DOIs | |
State | Published - Oct 2023 |
Keywords
- Financial toxicity
- Inflation Reduction Act
- Medicare
- Multiple myeloma
ASJC Scopus subject areas
- Hematology
- Oncology
- Cancer Research